Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
Summary analysis shows high response rates and manageable toxicities for HBI0101 CAR T-cell in R/R multiple myeloma, suggesting feasibility in an academic setting.
Key Points
This analysis aims to evaluate the safety and efficacy of HBI0101 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Evaluated patients with R/R multiple myeloma after at least 3 prior therapies.
Assessed the efficacy based on overall response rates and minimal residual disease negativity.
Monitored adverse events including cytokine release syndrome and other toxicities.
93% overall response rate and 71% complete response rate in evaluable patients.
77% achieved minimal residual disease negativity at 10⁻⁵ by flow cytometry.
Cytokine release syndrome occurred in 94.9% with manageable toxicity levels.